Fundraising Fox
Hallux
Laguna Hills, US · Founded 2012 · Delaware corporation · 1 known investors
Find your way into Hallux
Sign up to see every warm intro you have to Hallux
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hallux team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hallux Inc. develops Hallux Subungual Gel (HSG), a physician-administered terbinafine treatment applied directly to the nail bed to treat onychomycosis (fungal nail infection). The pharmaceutical product is being evaluated in clinical trials for use by podiatrists and dermatologists at the point-of-care.
Founders & leadership
HA
Hendrik Arend KroonExecutive
MT
Mark TaylorCo-Founder, CEOHe previously authored a book about Serbian pharmaceutical executive Milan Panic and the history of ICN Pharmaceuticals' antiviral drug development.
JB
Jay BirnbaumNamed on SEC filing
Board
PS
ZS
Zheng SuBoard director
BS
Bryan SendrowskiBoard director
Investors · 1
Deerfield Management CompanyreportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$20M disclosed across 3 rounds · 2015–2022
▶$10.7MraisedApr 2023 · 18 investors · PharmaceuticalsRule 506(b)
▶$10.7MraisedApr 2023 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark TaylorExecutive Officer, Director
- Seth BirnbaumDirector
- William ForbesDirector
- Robert OrrDirector
- Jay BirnbaumDirector
- Offering amount
- $11M
- Amount sold
- $10.7M
- Minimum investment
- $1K
- Proceeds to insiders
- $500K
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$2.2MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jay BirnbaumDirector
- Robert OrrDirector
- William P ForbesDirector
- MARK TAYLORExecutive Officer, Director, Promoter
- Peter SteelmanDirector
- Offering amount
- $3.7M
- Amount sold
- $2.2M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedDec 2015 · 20 investors · PharmaceuticalsRule 506(b)
▶$7.1MraisedDec 2015 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter SteelmanDirector
- Jay BirnbaumExecutive Officer, Director
- Zheng SuDirector
- Hendrik Arend KroonExecutive Officer
- Mark TaylorExecutive Officer, Director
- Bryan SendrowskiDirector
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- Minimum investment
- $1K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Hallux.
Frequently asked questions
- What does Hallux do?
- Hallux Inc. develops Hallux Subungual Gel (HSG), a physician-administered terbinafine treatment applied directly to the nail bed to treat onychomycosis (fungal nail infection). The pharmaceutical product is being evaluated in clinical trials for use by podiatrists and dermatologists at the point-of-care.
- Who are Hallux's investors?
- Hallux's investors include Deerfield Management Company.
- How much funding has Hallux raised?
- Hallux has disclosed $20M raised across 3 rounds.
- Where is Hallux headquartered?
- Hallux is headquartered in Laguna Hills, US.